Press Releases

Investors

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead Pharmaceuticals Doses First Patient in SEQUOIA Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
PASADENA, Calif. --(BUSINESS WIRE)--Aug. 8, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in SEQUOIA (AROAAT2001), a potentially pivotal Phase 2/3 clinical study of ARO-AAT, the company’s second generation subcutaneously administered RNA
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Fiscal 2019 Third Quarter Results
- Conference Call and Webcast Today at 4:30 p.m. EDT PASADENA, Calif. --(BUSINESS WIRE)--Aug. 5, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2019 third quarter ended June 30, 2019 . The company is hosting a conference call at 4:30 p.m.
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Third Quarter Results
PASADENA, Calif. --(BUSINESS WIRE)--Jul. 24, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 5, 2019 , at 4:30 p.m. EDT to discuss its financial results for the fiscal 2019 third quarter ended June 30, 2019 .
View HTML
Toggle Summary Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-ANG3
PASADENA, Calif. --(BUSINESS WIRE)--Jul. 16, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration ( FDA ) has granted orphan drug designation to ARO-ANG3 for the treatment of homozygous familial hypercholesterolemia (HoFH).
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Participate in Roth RNA Revolution Conference
PASADENA, Calif. --(BUSINESS WIRE)--Jul. 8, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that Bruce Given , M.D., Arrowhead’s chief operating officer and head of R&D, and Vincent Anzalone , CFA, Arrowhead’s vice president of investor relations, will participate in panel
View HTML
Toggle Summary Arrowhead Pharmaceuticals Receives Fast Track Designation for ARO-AAT for Treatment of Alpha-1 Liver Disease
PASADENA, Calif. --(BUSINESS WIRE)--Jun. 27, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration ( FDA ) has granted Fast Track designation to ARO-AAT, the company’s second generation subcutaneously administered RNA interference (RNAi)
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
PASADENA, Calif. --(BUSINESS WIRE)--Jun. 21, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on June 14, 2019 , the Compensation Committee of the Board of Directors approved "inducement" grants to 11 new
View HTML
Toggle Summary Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-APOC3
PASADENA, Calif. --(BUSINESS WIRE)--Jun. 21, 2019-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration ( FDA ) has granted orphan drug designation to ARO-APOC3 for the treatment of familial chylomicronemia syndrome (FCS).
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Present at Upcoming June 2019 Conferences
PASADENA, Calif. --(BUSINESS WIRE)--May 31, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Jefferies 2019 Global Health Care Conference – New York , June 4-7, 2019 June 6 , 9:30 a.m.
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Fiscal 2019 Second Quarter Results
— Conference Call and Webcast Today at 4:30 p.m. EDT PASADENA, Calif. --(BUSINESS WIRE)--May 8, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2019 second quarter ended March 31, 2019 . The company is hosting a conference call at 4:30 p.m.
View HTML